Action ONCR ONCORUS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Oncorus, Inc.

Actions

ONCR

US68236R1032

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Oncorus : Termination of Material Agreement - Form 8-K
PU
Nanocap Potential Breakout Watchlist (EPAZ, GCAN, IQST, ONCR)
AQ
ONCORUS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Oncorus Announces Workforce Reduction Plan
GL
Oncorus Announces Workforce Reduction Plan
AQ
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
GL
Oncorus : Termination of Material Agreement - Form 8-K
PU
ONCORUS, INC. : Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Change in Directors or Principal Officers (form 8-K)
AQ
ONCORUS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
ONCORUS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
ONCORUS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
ONCORUS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
GL
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
GL
ONCORUS, INC. : Regulation FD Disclosure (form 8-K)
AQ
ONCORUS, INC. : Regulation FD Disclosure (form 8-K)
AQ
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
GL
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
AQ
ONCORUS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ONCR
  4. Actualités Oncorus, Inc.
  5. Communiqués